Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Current Deferred Revenue (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Current Deferred Revenue for 8 consecutive years, with $5.4 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Current Deferred Revenue fell 79.99% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Jun 2025, down 79.99%, and an annual FY2024 reading of $368000.0, down 82.74% over the prior year.
  • Current Deferred Revenue was $5.4 million for Q2 2025 at Spero Therapeutics, down from $17.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $28.4 million in Q1 2024 and bottomed at $368000.0 in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $9.2 million, with a median of $8.3 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue surged 514.6% in 2022, then plummeted 94.32% in 2024.
  • Year by year, Current Deferred Revenue stood at $1.9 million in 2021, then soared by 234.95% to $6.2 million in 2022, then tumbled by 65.72% to $2.1 million in 2023, then tumbled by 82.74% to $368000.0 in 2024, then surged by 1375.82% to $5.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for SPRO at $5.4 million in Q2 2025, $17.2 million in Q1 2025, and $368000.0 in Q4 2024.